Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 247 followers
Latest posts
Last updated about 7 hours ago
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
about 7 hours ago
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP...
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
about 8 hours ago
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to...
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
2 days ago
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
4 days ago
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in...
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
11 days ago
First results to be presented in two ASCO oral presentations Data in...
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
14 days ago
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize...
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
17 days ago
Adam Kovalčík , 19, receives $100,000 Top Award for his development of...
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
18 days ago
Federal court jury found Amgen liable for violating antitrust and tort laws...
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
about 1 month ago
18 presentations across five cancer types include new insights on the potential...
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
about 1 month ago
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent...
Regeneron Reports First Quarter 2025 Financial and Operating Results
about 1 month ago
First quarter 2025 revenues of $3.0 billion ; GAAP diluted EPS of...
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
about 1 month ago
Approval of Lynozyfic is based on data showing deep and durable responses...